The listing of Aimei Vaccine on the Beijing Stock Exchange is expected to provide a replicable model for other Hong Kong-listed companies to return to the A-share market in the future. The company itself is also expected to become a highly recognizable vaccine leader on the Beijing Stock Exchange, ushering in a new starting point of value.

AIM Vaccines projects a significant reduction in losses for 2024, with revenue expected between RMB 1.25 billion and 1.3 billion, a 5%–9% year-on-year increase; net losses are expected to range from RMB 250 million to 290 million, reflecting an 85%–87% reduction in losses. This improvement is primarily due to reduced impairment losses and higher revenue from its hepatitis B vaccine.

AIM Vaccines announced two major updates on its rabies vaccine development: its serum-free rabies vaccine completed Phase III trials, obtained production licenses, and will be submitted for marketing registration; its high-potency human diploid rabies vaccine received approval to start clinical trials.

On March 9, AIM Vaccines announced that its independently developed high-potency human diploid rabies vaccine, which has been upgraded through iterative processes, recently received the "Approval Notice for Drug Clinical Trials" from the National Medical Products Administration. This vaccine is characterized by its exceptionally high potency.

As a leading company in China's vaccine industry, AIM Vaccines, supported by DeepSeek, has accelerated the R&D of its next-generation mRNA vaccines and expanded into overseas markets, emerging as a highly attractive investment opportunity.

Vaccine leader AIM Vaccines announced on February 23 a comprehensive deployment of the DeepSeek large model, leveraging localization strategies to integrate the DeepSeek R1 version across all business scenarios, achieving "cost reduction, quality improvement, and efficiency enhancement" throughout the vaccine lifecycle.